ストックスクリーナーアプリを入手
85.53
0.08%
-0.07
アフターアワーズ：
85.06
-0.47
-0.55%
Arrowhead Pharmaceuticals Inc (ARWR) 最新ニュース
BlackRock discloses 10.1% Arrowhead Pharmaceuticals (ARWR) stake in latest 13G/A - Stock Titan
Arrowhead Pharmaceuticals Advances Zodasiran Study for HoFH Trea - GuruFocus
Arrowhead Pharmaceuticals (ARWR) Completes Enrollment in YOSEMITE Trial - GuruFocus
H.C. Wainwright raises Arrowhead Pharma price target to $115 on trial data - Investing.com Canada
Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia - Arrowhead Pharmaceuticals, Inc.
Arrowhead's Rare Cholesterol Disease Study Reaches 70 Patients - Stock Titan
Arrowhead Pharmaceuticals Inc (ARWR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Arrowhead Pharmaceuticals, Inc. Revenue Breakdown – BX:HDP1 - TradingView
Arrowhead Pharmaceuticals, Inc. Revenue Breakdown – XETR:HDP1 - TradingView
Is Arrowhead Pharmaceuticals on the Cusp of a Major Breakout - Kavout | AI
Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Forecasts - Yahoo! Finance Canada
The 'Best-Case Scenario' That Shot Arrowhead Stock Sky-High - Investor's Business Daily
Is Arrowhead Pharmaceuticals Stock A Smart Buy After Its Transition To A Commercial Company? - Trefis
ARWR Reiterated by Piper Sandler -- Price Target Raised to $126 - GuruFocus
H.C. Wainwright reiterates Arrowhead Pharma stock rating on trial data By Investing.com - Investing.com Canada
Arrowhead shares surge as Phase III plozasiran studies deliver positive pancreatitis data - The Pharma Letter
Arrowhead Pharmaceuticals (ARWR) Hits 52-Week High Following Pos - GuruFocus
Arrowhead Pharmaceuticals (ARWR) Reports Positive Phase 3 Trial Results - GuruFocus
Arrowhead (ARWR) Sees Significant Stock Surge - GuruFocus
ARWR Stock Clocks Best Day In Nearly 8 Months As Analyst Lifts Price Target On Plozasiran Data - TradingView
Arrowhead Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $101.6, Implies 36% Upside - TradingView
ARWR Stock Climbs As EU Greenlights REDEMPLO And Analysts Boost Targets - timothysykes.com
Arrowhead rises on phase III hypertriglyceridemia readout - BioWorld News
ARWR Maintained by Chardan Capital -- Price Target Raised to $115 - GuruFocus
Arrowhead Pharmaceuticals Shares Rise After Phase 3 Trials of Plozasiran Meets Primary, Secondary Endpoints - Moomoo
Arrowhead Pharmaceuticals Inc Stock (ARWR) Closed Up by 19.04% on Jul 22: What Signal Does It Send? - TradingKey
ARWR Stock Climbs As EU REDEMPLO Win Fuels Bullish Targets - StocksToTrade
Why Arrowhead Pharmaceuticals Is Surging 24.4%: JP Morgan Maintains Overweight - AlphaStreet
Arrowhead Pharmaceuticals (NASDAQ:ARWR) shares rise 23% after Plozasiran Phase 3 data released - TechStock²
Arrowhead (ARWR) Soars to New High as Plozasiran Nears Expanded Commercialization - Yahoo Finance
ARWR Stock Climbs As REDEMPLO Win Fuels Bullish Targets - timothysykes.com
Arrowhead Drug Shows Strong Efficacy In Cutting Blood Fat - Benzinga
Plozasiran Phase III Results Expand Cardiometabolic Use - AllSci
ARWR Stock Climbs As EU Approval And Analyst Targets Heat Up - StocksToTrade
Arrowhead: Stock Up On SHTG DataNo Ceiling On Valuation Growth Potential (NASDAQ:ARWR) - Seeking Alpha
Arrowhead stock jumps on late-stage trial win (ARWR:NASDAQ) - Seeking Alpha
Arrowhead Pharmaceuticals (ARWR) Achieves Late-Stage Trial Succe - GuruFocus
H.C. Wainwright Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $100 - Moomoo
ARWR Stock Climbs As EU Greenlights REDEMPLO, Street Lifts Targets - StocksToTrade
Arrowhead hits ‘best-case scenario’ with latest results for fat-lowering drug - BioPharma Dive
Why is Arrowhead Pharmaceuticals stock surging today? - Investing.com
Look out Ionis, here comes Arrowhead with promising hypertriglyceridemia data - Fierce Pharma
Arrowhead (ARWR) Shares Surge Over 22% - GuruFocus
Arrowhead puts pressure on Ionis with positive data for triglyceride lowering drug - BioSpace
Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia - BioSpace
Arrowhead Pharmaceuticals: Redemplo Meets High Expectations In SHTG Trials (NASDAQ:ARWR) - Seeking Alpha
Arrowhead Pharmaceuticals stock hits 52-week high at $87.93 By Investing.com - Investing.com South Africa
Why is Arrowhead Pharmaceuticals stock surging today? By Investing.com - Investing.com Canada
ARWR Jumps As REDEMPLO Win Fuels Bullish Targets - StocksToTrade
Arrowhead Pharmaceuticals stock hits 52-week high at $87.93 - Investing.com
ARWR Stock On Track To Hit Over 5-Year Highs – Retail Cheers Phase 3 Breakthrough As Arrowhead Targets Broader FDA Approval - Yahoo Finance
Arrowhead Pharmaceuticals stock jumps on Phase 3 trial results - Investing.com
Arrowhead Pharmaceuticals shares surge after positive Phase 3 results for plozasiran (NASDAQ:ARWR) - Yahoo Finance
Ionis drops as Arrowhead posts late-stage trial win for lipid-lowering drug - Seeking Alpha
Arrowhead Pharmaceuticals stock jumps on Phase 3 trial results By Investing.com - Investing.com South Africa
1.97%
0.83%
大文字化:
|
ボリューム (24 時間):